ntionally to stay the course with the radical approach," said Vorstman. "The common post-operative complications associated with this radical surgical approach are impotence and incontinence (limp and leaking)—complications that result in a significant negative impact on QoL not only for the man, but his wife and their partnership."
Dr. Vorstman contends that surgeons eventually recognized this disposition for complications after surgical removal of the prostate, and refined their radical approach to prostate cancer treatment and developed the "nerve sparing" technique in attempts to lessen this propensity for "limp and leaking."
However, he said, this "nerve sparing" approach for prostate cancer excision did not realize the expected great improvement in results with better preservation of erectile function and urinary continence.
This dilemma, according to Dr. Vorstman, then led some surgeons to create "new" definitions for impotence and incontinence so that their radical surgery was now associated with acceptable levels of these complications.
Subsequently, when the biotech industry found a use for their robotic machines in prostate cancer treatment, technology firms soon discovered that they could report even more impressive post operative results.
"These impressive treatment results for radical surgery/robotics were achieved through the coupling of these spurious definitions for limp and leaking with more misleading information," he contends. "This so called data for the non FDA trialed treatment option was then spiced with unbridled and unabashed marketing and propelled into the forefront of prostate cancer treatment as some quasi gold standard."
In an extensive article http://www.hifurx.com/prostate-cancer/prostate-cancer-after-effects/ Dr. Vorstman details "The Good, The Bad and the Ugly" story behind prostate cancer and the inPage: 1 2 3 Related biology technology :1
. New Study Finds Cord Blood-derived Stem Cell Treatments Improve Ataxia Patients Functionality and Quality of Life2
. Crucial Directives Must be Revised to Protect Patients Interests and Improve Access to Treatment3
. Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients4
. Stem cell study offers hope for Parkinsons patients5
. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies6
. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients7
. RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece8
. Analysis Provides New Insights Into Use of SYMLIN® in Patients With Type 1 Diabetes Using Insulin Pumps9
. Pixantrone in Combination with Fludarabine, Dexamethasone and Rituximab Produces High Rates of Complete Remissions in Patients with Relapsed or Refractory Indolent Non-Hodgkins Lymphoma10
. ACT Announces First Patients Enrolled in Two Clinical Trials Using Embryonic Stem Cells to Treat Stargardts Disease and Dry Age-Related Macular Degeneration11
. Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome